Clik here to view.
MetLife’s 360Health Wins Gold Stevie®
HONG KONG MetLife’s 360Health has outshined several insurers and non-insurers to win the Gold Stevie® Award for Innovation in Heath & Wellness at the seventh annual Asia-Pacific Stevie Awards....
View ArticleClik here to view.
Intralink-Spine, Inc. Adds Clinical Sites in Australia
LEXINGTON, Ky. Intralink-Spine, Inc. (ILS) announces the expansion of clinical trials for their patented injectable medical device, Réjuve ®, intended in Australia for the treatment of low back...
View ArticleClik here to view.
FDA核准HD Medical的HD Steth
加州圣克拉拉 (美国商业资讯)–位于硅谷的HD Medical, Inc.今天宣布，FDA已全数核准其旗舰产品HD Steth对应电子听诊器、心音图、心电图一体化器械的3个产品分类代码DQD、DQC和DPS。HD Steth采用尖端AI技术，使临床工作者能在医护现场实施高级心脏评估，从而节省时间、挽救生命。 本新闻稿包含多媒体。此处查看新闻稿全文：...
View ArticleClik here to view.
HDメディカルがHD StethのFDA認可を取得
米カリフォルニア州サンタクララ （ビジネスワイヤ） — シリコンバレーのHDメディカルは本日、当社の主力製品HD Steth（HDステス）が電子聴診器、心音計、心電計の機能を1つの装置に統合し、DQD、DQC、DPSという3つの製品分類コードでFDA認可を取得したことを発表します。HD...
View ArticleClik here to view.
RIBOMIC Announces Dosing of First Subject in RBM-007 Phase 1 Clinical Trial...
TOKYO RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics and traded on the Mothers Market of the Tokyo Stock Exchange (TOKYO:4591), today announced that the...
View ArticleClik here to view.
Global Demand for Innovation Prevails Over Challenges of COVID-19: New Report...
LONDON & BOSTON & TOKYO The impact of COVID-19 has so far wiped $7.85bn off forecasts for biopharma sales in 2020, with the top 15 companies bearing 60% of that loss, according to the...
View ArticleClik here to view.
NICEがフラットアイアン・ヘルスと提携し、実臨床データに基づく研究方法の開発へ
英マンチェスター & ニューヨーク （ビジネスワイヤ） — 英国国立医療技術評価機構（NICE、 www.nice.org.uk）は対ガン剤の研究と技術開発を手掛ける企業であるフラットアイアン・ヘルス（ www.flatiron.com）と提携しています。この連携は、実臨床データを通して医療技術の臨床有用性と医療経済性を評価することを目標としています。...
View ArticleClik here to view.
New Study Expands Evidence Demonstrating the Benefits of Critical Congenital...
NEUCHATEL, Switzerland Masimo (NASDAQ: MASI) today announced the results of a prospective study published in the International Journal of Neonatal Screening in which researchers in Marrakesh,...
View ArticleClik here to view.
JW Therapeutics Acquires Syracuse Biopharma and License to Eureka...
SHANGHAI & EMERYVILLE, Calif. JW Therapeutics, a clinical stage biopharmaceutical company focused on developing, manufacturing and commercializing cell therapies for patients in China, today...
View ArticleClik here to view.
BostonGene and NEC Collaborate to Analyze Cancer Patients in Clinical Trials
WALTHAM, Mass. & TOKYO BostonGene Corporation (BostonGene), a biomedical software company focused on defining optimal precision medicine-based therapies for cancer patients, and NEC Corporation...
View ArticleClik here to view.
新研究的扩大证据显示Masimo SET®脉搏氧饱和度仪筛查危重型先天性心脏病(CCHD)的收益
瑞士纳沙泰尔 (美国商业资讯)–Masimo (NASDAQ: MASI)今天发布《国际新生儿筛查杂志》(International Journal of Neonatal Screening)发表的一项前瞻性研究结果，该研究中，摩洛哥马拉喀什的研究人员开展摩洛哥首次Masimo...
View ArticleClik here to view.
Masimo SET®パルスオキシメトリーを使用した重篤先天性心疾患（CCHD）スクリーニングの利点を示す証拠を積み増す新研究
スイス・ヌーシャテル （ビジネスワイヤ） — マシモ（NASDAQ: MASI）は本日、International Journal of Neonatal Screening誌に掲載された前向き研究の結果を発表しました。この研究では、モロッコのマラケシュの研究者らが、Masimo...
View ArticleClik here to view.
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for...
TOKYO & BASKING RIDGE, N.J. & MUNICH & VILLEJUIF, France Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) and Gustave Roussy today announced a multi-year, multi-study research...
View ArticleClik here to view.
Terns Pharmaceuticals Announces Initiation of Patient Dosing in the LIFT...
FOSTER CITY, Calif. & SHANGHAI Terns Pharmaceuticals, Inc., a global biopharmaceutical company focused on discovering and developing innovative therapies to treat non-alcoholic steatohepatitis...
View ArticleClik here to view.
拓臻生物宣布其非酒精性脂肪性肝炎（NASH）候选药物TERN-101的Ⅱa期临床试验(LIFT) 完成首位患者给药
美国加州福斯特城与中国上海 (美国商业资讯)–Terns Pharmaceuticals 拓臻生物—一家专注肝脏疾病和癌症创新疗法研发的国际生物制药公司，今天宣布在名为LIFT的TERN-101的Ⅱa期临床试验中完成首位患者给药。TERN-101是一种具有肝脏选择性的法尼醇X受体（FXR）激动剂，是公司开发的针对非酒精性脂肪性肝炎（NASH）适应症的主要候选药物之一。...
View ArticleClik here to view.
Terns Pharmaceuticals、NASH治療薬として開発中のTERN-101の第2a相臨床試験LIFTで患者への投与を開始したと発表
米カリフォルニア州フォスターシティ & 上海 （ビジネスワイヤ） — 非アルコール性脂肪肝炎（NASH）とがんの革新的治療薬の創薬と開発に傾注する世界的バイオ製薬会社のTerns Pharmaceuticals,...
View ArticleClik here to view.
Hansoh Pharma Announces Strategic Collaboration and Licensing Agreement for...
SHANGHAI Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”; 3692.HK), a leading biopharmaceutical company in China, today announced a strategic collaboration and licensing agreement for...
View ArticleClik here to view.
Noxopharm Reports Idronoxil Achieves Major Industry Goal of Converting ‘Cold’...
SYDNEY Noxopharm, a clinical-stage Australian oncology drug development company listed on the ASX (ASX:NOX), has claimed a breakthrough in the search for restoring immune function within “cold”...
View ArticleClik here to view.
joimax® Expands Presence in Australia
KARLSRUHE, Germany joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is pleased to announce a new partnership...
View ArticleClik here to view.
CORRECTING and REPLACING Hansoh Pharma Announces Strategic Collaboration and...
SHANGHAI First paragraph, fourth sentence of the release should read: Hansoh will receive approximately $100 million in upfront payment and development and regulatory milestones, with additional...
View Article